AHB
VRTX icon

Abner Herrman & Brock’s Vertex Pharmaceuticals VRTX Stock Holding History

Abner Herrman & Brock’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,430
Closed -$2.28M – 126
2019
Q4 		$2.28M Buy
+10,430
New +$2.11M 0.34% 49

Other funds holding VRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Abner Herrman & Brock's VRTX Position: Q1 2020 in Review

Abner Herrman & Brock sold out of Vertex Pharmaceuticals (VRTX) in Q1 2020, closing a stake of 10,430 shares — an estimated $2.28M sold.

Abner Herrman & Brock first reported a position in VRTX in Q4 2019 and held it in 1 quarter. The position peaked at $2.28M in Q4 2019. 855 funds tracked by Wall St. Rank hold VRTX as of Q1 2020.

  • Abner Herrman & Brock reported no remaining Vertex Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Abner Herrman & Brock sold 10,430 Vertex Pharmaceuticals shares in Q1 2020, an estimated $2.28M.
  • Abner Herrman & Brock first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Abner Herrman & Brock's Vertex Pharmaceuticals position peaked at $2.28M in Q4 2019.
  • 855 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2020.

Based on Abner Herrman & Brock's 13F filing for Q1 2020, filed 9 Apr 2020.